E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
biliary tract cancer not amedable for curative resection with progressive disease after first-line chematherapy with gemcitabine and cisplatin |
Metastasierte oder lokal fortgeschrittene, nicht operable Tumoren des biliären Systems (Gallengangs-, Gallenblasen- sowie Papillenkarzinome), die eine progrediente Erkrankung unter einer Erstlinienchemotherapie mit Gemcitabin- und platinhaltigen Chemotherapie zeigten. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients suffering from cholangiocarinoma or gallbladder cancer without possibility for resection and disease progress after therapy with gemcitabine and cisplatin. |
Fortgeschrittener Tumor der Gallenblase oder -wege, der nicht operiert werden kann. Nach Chemotherapie mit Gemcitabin und einem Platinderivat kam es zu einem Voranschreiten der Erkrankung. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Determination of the progression free survival (PFS) in FOLFIRI arm > 2 months |
|
E.2.2 | Secondary objectives of the trial |
Determination of
• overall survival (OS)
• time to progression (TTP) by RECIST 1.1
• overall response rate (either complete response, CR, or partial response, as measured by RECIST 1.1
• safety profile
• quality of life (EORTC QLQ-C30 questionnaire)
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Translation Research Program (see section 12.3. in the protocol). |
|
E.3 | Principal inclusion criteria |
• Written informed consent granted prior to initiation of any study specific screening procedures
• Patients with histologically confirmed CCA or GB-CA not suitable for resection or metastatic
• Progressive disease undergoing a systemic chemotherapy with a platin-derivate (Oxaliplatin, Cisplatin or Carboplatin) or progressive disease within 3 months after cessation of chemotherapy
• Age >= 18 years
• Performance status ECOG 0-2
• Normal organ and bone marrow function defined as:
o Hematopoetic: absolute neutrophil count >1,500/mm3, platelet count >75,000/mm3, hemoglobin >9 g/dL
o INR ≤ 1.5
o Hepatic: AST or ALT < 5 x ULN, bilirubin ≤ 2 mg/dl
o Renal: serum creatinine < 1.5 x ULN
• Child Pugh stage A in patients with cirrhosis
• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the randomization
• Male or female patients of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose received
|
|
E.4 | Principal exclusion criteria |
• CCA or GB-CA amendable for surgical resection
• Prior radiation therapy, chemoradiation, transarterial chemoembolisation (TACE), Radiofrequency ablation (RFA) or selective intraarterial Radiotherapy (SIRT) within the last 3 months, radiation of symptomatic bone metastasis is allowed
• Concomitant photodynamic therapy or intraductal radiofrequency ablation within the last 8 weeks
• Child Pugh stage B or C (> 6 points) in patients with cirrhosis (Appendix 21.3)
• Massive, uncontrolled ascites
• Systemic anticancer chemotherapy other than Gemcitabin and a platin derivate (Cisplatin, Carboplatin or Oxaliplatin)
• Cardiac disease: congestive heart failure > class II NYHA
• Known uncontrolled brain metastasis
• History of bone marrow or organ allograft
• Active clinically serious infections > CTCAE grade 2 beside of chronic hepatitis C virus infection
• Major surgery within 4 weeks of first dose of study drug, port implantation is allowed
• Known or suspected allergies to 5-FU, folinic acid or irinotecan
• Previous cancer that is distinct in primary site or histology from CCA or GB-CA except cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors or any cancer curatively treated 3 years prior to study entry
• Substance abuse, medical or psychological condition that may interfere with the patient´s participation in the study
• Participation in another clinical trial with any investigational study drug (whatever the use, curative, prophylactic or diagnostic intent) within 30 days prior to enrollment
• Pregnancy or breast feeding women
• Incapability to give valid informed consent (including patients who are dependent on the sponsor or the investigator)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Determination of the progression free survival (PFS) in FOLFIRI arm > 2 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- overall survival (OS)
- time to progression (TTP) by RECIST 1.1
- overall response rate (either complete response, CR, or partial response, as measured by RECIST 1.1
- safety profile
- quality of life (EORTC QLQ-C30 questionnaire)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- overall survival (OS): every visit
- time to progression (TTP) by RECIST 1.1: every 8 weeks
- overall response rate (either complete response, CR, or partial response, as measured by RECIST 1.1: every 8 weeks
- safety Profile: every visit
- quality of life (EORTC QLQ-C30 questionnaire): every 2 weeks
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Translational Research Program:
Additonal blood samples for translational research will be taken if patient gives consent. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
comparison to standard therapy with 5-Fluorouracil (5-FU) and Folinicc Acid |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is reached if all patients finished the follow-up period which starts 30 days after the last study treatment administration until death. survival Information will be collected every 6 weeks. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |